Gene CcCp1 of Colletotrichum camelliae and its application
By regulating the expression of CcCp1, the drug was developed to reduce its pathogenicity and spore production, and the problem of anthrax infection in tea trees was solved and the disease resistance of tea trees was significantly improved.
Patent Information
- Application Number
- CN202211669315.6
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2022-12-24
- Publication Date
- 2024-11-01
- Estimated Expiration
- 2042-12-24
AI Technical Summary
The existing technology is difficult to effectively control the mycelial expansion rate, spore production and pathogenicity of Camellia ceramide, resulting in serious damage to anthrax infection in plants such as tea trees.
The gene CcCp1 and its knockout vector were proposed. By regulating the expression of the CcCp1 gene and the modification and localization of proteins, the agent was developed to reduce the pathogenicity and spore production of the Camellia CcCp1 gene and improve the disease resistance of the tea tree. sex.
Through the deletion of the CcCp1 gene, the pathogenicity and mycelial growth rate of camellia ceramide and increased the disease resistance of tea trees, and provided new targets for the development of anti-cake ceramide and ceramide agents.
Smart Images

Figure CN118240041B_ABST
Abstract
Description
Technical Field
[0001] The present invention belongs to the field of plant genetic engineering, and specifically relates to a gene of Colletotrichum spp. CcCp1 It is used to control the hyphae expansion rate, spore production and pathogenicity of Colletotrichum japonicum. Background Art
[0002] Anthrax was first isolated and observed in 1790 and classified as Vermicularia; in 1831, the fungus with bristles on its conidia was separated and an independent genus, Anthrax, was established. Colletolrichum Corda ). Some researchers isolated the anthracnose pathogen from tea trees in different tea-producing areas in my country and found that C. camelliae , C. fructicola , C. gloeospori , C. siamense , C. henanense and C. jiangxiense 6 anthrax species were found C. camelliae It is widely distributed in major tea-producing areas in my country and has certain harm to most varieties of tea trees in my country, so it can be inferred that C. camelliae It is the main dominant species that harms tea trees in China.
[0003] Plant anthracnose bacteria mainly infect the leaves of plants. In the early stage of anthracnose infection, only the edges of the leaves will be affected by anthracnose; as the disease progresses, the diseased part gradually spreads to the middle or most of the leaves, usually causing the entire leaf to wither and turn black and die. In the early stage of anthracnose, only some oval or round reddish-brown spots will appear on the leaves of the plant. In the later stage of anthracnose development, these spots will become dark brown round spots with a diameter of about 1~4mm. The edges of the spots have yellow halos and appear purple-brown or dark green. In the late stage of anthracnose development, the spots completely change from dark brown to black brown, and some small black spots in the shape of rings will appear, indicating that the pathogen has grown conidia. When the spots are too many and too dense, the leaves of the plant will wither and fall off. In addition to occurring on the leaves of the plant, anthracnose will also infect the tender stems of the plant. When the disease occurs on the stem, some round and oval spots are usually produced. When anthracnose fungi infect the tender shoots of plants, the lesions generally appear as oval ulcerated spots.
[0004] Plant pathogenic fungi secrete a large number of proteins that are involved in various aspects of parasitism and disease development, such as transmission through vectors, attachment to plant organ surfaces, expression of symptoms, and induction of defense responses. Among these proteins, there are various types of enzymes, receptors, and cysteine-rich secreted proteins. This large group of cysteine-rich proteins is highly diverse, and Templeton et al. classified them based on the number of cysteines, molecular weight, and role in pathogenicity. Currently, seven families of non-catalytic fungal proteins have been identified based on their primary sequences, including the certo-platanin (CP) family (PF07249), class I hydrophobins (PF01185), class II hydrophobins (PF06766), elicitins (PF00964), PcF family (PF09461), and NIP-1 family (PF08995). Among them, CP proteins are a class of proteins unique to fungi. Summary of the invention
[0005] The present invention provides a gene of Colletotrichum camelliae CcCp1 , whose nucleotide sequence is shown in SEQ ID NO: 1, encoding CcCp1 The amino acid sequence of the protein is shown in SEQ ID NO: 2. CcCp1 It is derived from Colletotrichum camelliae and is involved in controlling the mycelial expansion rate, spore production and pathogenicity of the fungus. The present invention also proposes a gene of Colletotrichum camelliae CcCp1 Application of knockout vectors and knockout mutants 。 Due to the CcCp1 The deletion of the gene reduces the pathogenicity of Colletotrichum japonicum to host plants. CcCp1 The gene and the protein it encodes can be used as targets in the development of anti-Camellia thorny Colletotrichum drugs, and the screening of compounds that can inhibit the activity of the gene and the expression, modification and localization of its protein can effectively control the occurrence of Camellia thorny Colletotrichum. The drug contains a compound that blocks or inhibits the activity of Camellia thorny Colletotrichum. CcCp1 Genetic engineering vectors for gene expression, such as knockout vectors, are used to reduce the pathogenicity of Colletotrichum camelliae or reduce the spore production of Colletotrichum camelliae or induce disease resistance in tea plants.
[0006] The purpose of the present invention is to provide a kind of camellia thorn colleorium CcCp1 Gene or CcCp1 Application of protein as control target in the preparation of anti-Camellia spinulosa drug.
[0007] Furthermore, the agent is used for any one or more of A to C: A. regulating the hyphae expansion rate of Colletotrichum camelliae; B. regulating the spore production of Colletotrichum camelliae; C. regulating the pathogenicity of Colletotrichum camelliae.
[0008] Furthermore, the Colletotrichum camelliaeCcCp1 Gene activity or CcCp1 Increased protein expression promotes the pathogenicity of Colletotrichum camelliae, the Colletotrichum camelliae CcCp1 Gene activity or CcCp1 Loss of protein expression reduces the pathogenicity of Colletotrichum camelliae.
[0009] Furthermore, the regulation of the pathogenicity of Colletotrichum camelliae is achieved by improving the tea tree oil metabolism pathway.
[0010] Furthermore, the medicament comprises CcCp1 Gene inhibitors or CcCp1 Gene knockout vector.
[0011] Furthermore, the reduction of pathogenicity of Colletotrichum camelliae is achieved by improving the tea tree oil metabolism pathway.
[0012] Furthermore, the plant is a host plant of Colletotrichum camelliae.
[0013] Furthermore, the host plant is one of the plants of the genus Camellia, such as tea tree, oil tea, and camellia.
[0014] Another object of the present invention is to provide a CcCp1 Application of genes in improving disease resistance of Camellia plants, using CcCp1 Gene-deficient Colletotrichum camelliae induces plants to develop immunity to Colletotrichum camelliae.
[0015] Furthermore, the plant is a host plant of Colletotrichum camelliae.
[0016] Furthermore, the host plant is one of the plants of the genus Camellia, such as tea tree, oil tea, and camellia.
[0017] Another object of the present invention is to provide a method for preventing and controlling Colletotrichum camelliae, wherein the knockout expression vector blocks or inhibits Colletotrichum camelliae. CcCp1 By regulating the expression of genes, biocontrol strains with reduced pathogenicity are obtained.
[0018] The present invention provides CcCp1 An important use of the gene is that the expression of the gene and the protein product it encodes can be used as an important candidate target site for the design and screening of anti-Camellia thorny spore drugs. CcCp1 The deletion of the gene significantly reduced the pathogenicity of Colletotrichum camelliae, slowed the growth of mycelium and reduced the spore production. Therefore, screening compounds that can prevent the expression of this gene and the expression, modification and localization of its protein can effectively control the occurrence of Colletotrichum camelliae, thereby contributing to the development of new fungicides. BRIEF DESCRIPTION OF THE DRAWINGS
[0019] Figure 1 Colletotrichum spp. CcCp1 Schematic diagram of gene knockout strategy (gene replacement by homologous recombination); CCA is the wild-type strain, pXEH is the knockout vector, Δ CcCp1 for CcCp1 Gene deletion mutants.
[0020] Figure 2 for CcCp1 Schematic diagram of qPCR expression of gene deletion mutants.
[0021] Figure 3 The knockout mutant Δ CcEpl Wild-type strain Colletotrichum camelliae Mycelial extension rate; where Δ CcCp1- 9. Δ CcCp1- 14 and Δ CcCp1- 15 is a knockout mutant, Colletotrichum camelliae The wild type.
[0022] Figure 4 The knockout mutant Δ CcCp1 Wild-type strain Colletotrichum camelliae and complement Δ CcCp1- Comparative analysis of conidia production in C; CcCp1- 9 and Δ CcCp1- 14 is a knockout mutant, CCA is the wild type, Δ CcCp1- C is the complement.
[0023] Figure 5 The knockout mutant Δ CcCp1 Wild-type strain Colletotrichum camelliae and overexpression mutant Δ CcCp1- Comparative analysis of pathogenicity of C; among which Δ CcCp1 For knockout mutants, Colletotrichum camelliae is the wild type, Δ CcCp1- C is an overexpression mutant, and the host is tea leaves. DETAILED DESCRIPTION
[0024] The present invention is further defined in the following examples. Based on the following description and these examples, those skilled in the art can ascertain the essential characteristics of the present invention and, without departing from the essence and scope of the present invention, can make various changes and modifications to the present invention to adapt it to various uses and conditions.
[0025] Unless otherwise specified, the experimental methods used in the following examples are all conventional methods; the materials, reagents, etc. used, unless otherwise specified, can be obtained from commercial channels.
[0026] Embodiment 1,CcCp1 Gene knockout and genetic complementation
[0027] 1) Knockout vector construction strategy Figure 1 As shown. First, the target gene DNA flanking sequence was amplified. Primers were designed using DNAMAN and synthesized by Shanghai Shenggong Biotechnology Co., Ltd. CcCp1 -UP-F: 5'-GGCGGCCTCGAGGGATGTTGTTTGCCTGCG-3' (SEQ ID NO:3) with CcCp1 -UP-R: 5'-CGGGGTACCTTTGGCGGTTGTGGGTGGA-3' (SEQ ID NO: 4) with anthrax strains Colletotrichum camelliae Amplification of genomic DNA as template CcEpl The upstream fragment of the gene is about 1 kbp; the primers CcCp1 -DN-F: 5'-GCTCTAGAACCACCACACGACCTCGG-3' (SEQ ID NO:5) and CcCp1 -DN-R: 5'-ACGCGTCGACGACCCACATGCAGCTCCGA-3' (SEQ ID NO: 6), based on anthrax strains Colletotrichum camelliae CCA genomic DNA as template for amplification CcEpl A fragment of about 1 kbp downstream of the gene. Reaction system (25 μL): Takara PrimerSTAR Max DNA Polymerase (2×) 12.5 μL; upstream and downstream primers (10 μM) 1 μL each; template DNA 1 μL; ddH2O 9.5 μL. Amplification procedure: (1) 98°C for 10 s; (2) 53°C for 15 s; (3) 72°C for 10 s, and cycle steps 1-3 35 times. Use the TAKARA gel recovery kit to recover and purify the PCR product. Use XhoI + KpnI as well as XbaI + SalI The upstream and downstream fragments were connected to the pXEH vector to construct a knockout vector.
[0028] SEQ ID NO: 1 Nucleotide sequence: 417 bp
[0029] ATGCAGTTCT CCAACCTTGT CACCATCCTC TCCTCCGTCG CCGCGGCCGC GGCCGTCTCC
[0030] GTCTCCTTCG ACACCGGCTA TGATGACGGT GCCCGCTCCC TCACTGCCGT CTCCTGCTCC
[0031] GACGGCGCCA ACGGCCTGAT CACCAAGTAC AACTGGCAAA CCCAGGGCAA CATCGCCCGC
[0032] TTCCCCTACA TCGGTGGTTC CGACGCCGTT GCCGGCTGGA ACTCCCCCAA CTGCGGCACC
[0033] TGCTGGCAGC TCACCTACAA CGGCAAGAGC ATCAACGTCC TCGCCATCGA CCACGCCGGC
[0034] TCCGGCTTCA ACCTCGCCCT CGGCGCCATG AACGACCTCA CCAACGGCCA GGCCAACCAG
[0035] CTCGGCCGCA TCGACGCCCA GGCCACCCAG GTCGCCCTCA GCGCCTGCGG TCTGTAA
[0036] SEQ ID NO:2 amino acid sequence:
[0037] MQFSNLVTIL SSVAAAAAVS VSFDTGYDDG ARSLTAVSCS DGANGLITKY NWQTQGNIARFPYIGGSDAV AGWNSPNCGT CWQLTYNGKS INVLAIDHAG SGFNLALGAM NDLTNGQANQ LGRIDAQATQVALSACGL*
[0038] 2) Transformation of Anthrax
[0039] A. Cultivation of Agrobacterium tumefaciens AGL-1: Pick the CcCp1 A single colony of the Agrobacterium tumefaciens strain AGL-1 was inoculated into LB liquid medium containing 50 μg / mL kanamycin and 25 μg / mL rifampicin, and cultured for 36 h until OD 600=0.8. Prepare IM liquid culture medium (100mL: 90mL ddH2O; 1mL 50% glycerol; 1mL 20% glucose; 4mL 1MMES; 2mL M-Nbuffer; 1mL Tracelement; 80μL K-buffer; 250μL 20% NH4N03; 100μL 1% CaCl2; 1mL 0.01% FeSO4; 200μL 19.2% As). First, add 1% 1% 1% 2 ... Add drugs except FeS04 and As to ddH2O, mix well, take 5 ml of the shaken bacterial liquid and put it in a 15 ml centrifuge tube, centrifuge at 4000 rpm for 5 minutes, discard the supernatant, add 5 ml of IM culture medium (without FeSO4, As), blow it, centrifuge at 4000 rpm for 5 minutes, discard the supernatant, add FeSO4 and As to the IM culture medium, take 5 ml and put it into a 15 ml centrifuge tube, blow it and transfer to an empty bottle, shake it at 28℃ shaker for 4 hours, and put the remaining IM liquid culture medium in a 4℃ refrigerator and wrap it in newspaper.
[0040] B. Spore culture of anthrax: activation Colletotrichum camelliae The strain was inoculated with a cake of PDB medium (20% boiled and filtered potato, 2% glucose) and cultured at 28°C for 3-8 days. The supernatant was filtered with gauze and observed under a microscope. The spore concentration was adjusted to 5×10 using a hemocytometer. 5 / mL.
[0041] C. Co-culture of Agrobacterium tumefaciens and conidia of anthrax pathogens: Mix equal volumes of Agrobacterium culture solution induced in IM liquid medium and anthrax spores of adjusted concentration, take 100 μL and spread on IM solid medium with cellophane, spread on 6 plates, seal the plates, and culture at 28°C in the dark for 2 days. After co-culture, transfer the cellophane to PDA medium containing 100 μg / mL hygromycin and continue to culture under the same conditions. After 4 to 7 days, pick the expanded colonies and place them on the screening medium containing the same antibiotics for secondary screening.
[0042] D. Verification of transformants: Use CcCp1 Gene primers were used to screen transformants by qPCR amplification. CcCp1 If the gene is missing, transcription cannot proceed smoothly. CcCp1 The gene qPCR primers 5'-GCAAACCCAGGGCAACAT-3' (SEQ ID NO:7) and 5'-ATGGCGAGGACGTTGATG-3' (SEQ ID NO:8) could not detect its expression. Figure 2 As shown, instructions for use CcCp1 Gene qPCR primers, wild-type cDNA has expression level while knockout body Δ CcCp1- 9. Δ CcCp1-14 and Δ CcCp1- 15 No expression. Three independent strains were screened from the transformants. CcCp1 Gene deletion mutant Δ CcCp1- 9. Δ CcCp1- 14. Δ CcCp1- 15 for subsequent functional analysis.
[0043] Embodiment 2, CcCp1 Effects of genes on hyphal extension rate of Colletotrichum camelliae.
[0044] activation Colletotrichum camelliae , Δ CcCp1 strain, make a 0.6 cm bacterial cake and inoculate it in the center of a 9 cm PDA culture plate, and place it in a 28°C incubator in the dark. Measure the colony diameter every 24 hours until a colony covers the entire plate, and knock out the mutant Δ CcEpl Wild-type strain Colletotrichum camelliae Mycelial extension rate Figure 3 shown.
[0045] Embodiment 3, CcCp1 Effects of genes on conidia production of Colletotrichum camelliae.
[0046] Each strain was cultured under the same culture conditions until all strains were spread on the plate. 5 mL of sterile water was added to the plate. The mycelia on the surface of the culture medium was scraped thoroughly with a cotton swab. After filtering the mycelia in the liquid with three layers of lens paper, the number of spores in the liquid was observed under a microscope. The mutant Δ CcEpl Wild-type strain Colletotrichum camelliae Mycelial extension rate Figure 4 shown.
[0047] Embodiment 4, CcCp1 Verification of the role of genes in the pathogenicity of Colletotrichum spp.
[0048] Spore inoculation: Each strain was cultured under the same culture conditions to produce spores, the spores were collected and concentrated, and the spores obtained by centrifugation were diluted to 1×10 6 / mL and mix thoroughly. Use a pipette to draw 20μL of spore liquid and drip it onto both sides of the leaves of the same batch of host plants of the same size and in good condition. Keep the inoculated host moisturized and cultured. Pay attention to the disease situation and take photos to record it. Inoculation of bacterial cake: activate the strain on PDA. When it grows for 4 days, use a puncher to punch out a uniform bacterial cake, turn it upside down on the leaves of the host plant, keep the inoculated host moisturized and cultured. Pay attention to the disease situation and take photos to record it. By combining spore liquid and bacterial cake, the differences in pathogenicity of wild type, knockout and complement to host plants were explored. The results are as follows. Figure 5 Shown: When knocking out CcCp1After the gene was added, the pathogenicity of anthrax to host plants was greatly reduced, while the pathogenicity of the complement was basically the same as that of the wild type, indicating that CcCp1 It is involved in regulating the pathogenicity of anthrax to host plants and is an indispensable key gene for anthrax to maintain its virulence to host plants.
[0049] The above embodiments illustrate the present invention of Colletotrichum camelliae CcCp1 Gene or CcCp1 The protein can be used as a control target in the preparation of anti-Camellia thorny Colletotrichum medicaments, and is used to regulate the hyphae expansion rate of Camellia thorny Colletotrichum , the spore production of Camellia thorny Colletotrichum , and the pathogenicity of Camellia thorny Colletotrichum . CcCp1 Gene activity or CcCp1 Increased protein expression promotes the pathogenicity of Colletotrichum camelliae, the Colletotrichum camelliae CcCp1 Gene activity or CcCp1 The loss of protein expression reduces the pathogenicity of Colletotrichum camelliae. The regulation of the pathogenicity of Colletotrichum camelliae is achieved by improving the tea tree oil metabolism pathway. The agent includes CcCp1 Gene inhibitors or CcCp1 Gene knockout vector.
[0050] The above embodiments are merely examples for the purpose of clear explanation, and are not intended to limit the implementation methods. For those skilled in the art, other different forms of changes or modifications can be made based on the above description. It is not necessary and impossible to list all the implementation methods here. The obvious changes or modifications derived therefrom are still within the scope of protection of the present invention.
Claims
1. Colletotrichum spp. CcCp1 Application of gene as control target in the preparation of anti-Camellia thorny Colletotrichum medicament, the CcCp1 The knockout of the gene reduced the pathogenicity of Colletotrichum camelliae to the host plant; Colletotrichum camelliae CcCp1 The nucleotide sequence of the gene is shown in SEQ ID NO:
1. The medicament is used for any one or more of A to C: A. Reduce the hyphae expansion rate of Colletotrichum japonicum; B. Reduce the spore production of Colletotrichum japonicum; C. Reduce the pathogenicity of Colletotrichum japonicum.
2. Colletotrichum spp. CcCp1 Application of protein as a control target in the preparation of an anti-Camellia thorny Colletotrichum medicament, the CcCp1 Loss of protein expression reduces the pathogenicity of Colletotrichum camelliae; Colletotrichum camelliae CcCp1 The amino acid sequence of the protein is shown in SEQ ID NO: 2; The medicament is used for any one or more of A to C: A. Reduce the hyphae expansion rate of Colletotrichum japonicum; B. Reduce the spore production of Colletotrichum japonicum; C. Reduce the pathogenicity of Colletotrichum japonicum.
3. The use according to claim 1 or 2, characterized in that: The Colletotrichum camelliae CcCp1 Gene activity or CcCp1 Increased protein expression promotes the pathogenicity of Colletotrichum camelliae, the Colletotrichum camelliae CcCp1 Gene activity or CcCp1 Loss of protein expression reduces the pathogenicity of Colletotrichum camelliae.
4. The use according to claim 1 or 2, characterized in that: The regulation of the pathogenicity of Colletotrichum camelliae is achieved by improving the tea tree oil metabolism pathway.
5. The use according to claim 1, characterized in that: The pharmaceutical agent includes CcCp1 Gene inhibitors or CcCp1 Gene knockout vector.
6. Colletotrichum spp. CcCp1 Application of genes in improving disease resistance of Camellia plants, using CcCp1 Gene-deficient camellia thorny spore fungus induces plants to produce immunity to camellia thorny spore fungus, and the camellia thorny spore fungus CcCp1 The nucleotide sequence of the gene is shown in SEQ ID NO:
1.
7. The use according to claim 6, characterized in that: The plant is a host plant of Colletotrichum camelliae.
8. The use according to claim 7, characterized in that: The host plant is a tea tree of the genus Camellia.
9. The use according to claim 8, characterized in that: The camellia tea tree is oil tea or camellia japonica.
10. A method for preventing and controlling Colletotrichum spp., characterized in that: pass CcCp1 Gene knockout vector blocks or inhibits Colletotrichum camelliae CcCp1 Gene expression, to obtain a biocontrol strain with reduced pathogenicity, the camellia thorn colletotrichum CcCp1 The nucleotide sequence of the gene is shown in SEQ ID NO:1.
